Anxiolytic-like effects of restraint during the dark cycle in adolescent mice

Ota, Yuki; Ago, Yukio; Tanaka, Teruhisa; Hasebe, Shigeru; Toratani, Yui; Onaka, Yusuke; Hashimoto, Hitoshi; Takuma, Kazuhiro; Matsuda, Takehisa

doi:10.1016/j.bbr.2015.02.010

Cited by 10 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the locomotor activity of control mice at ZT19 was high and that at ZT7 was low (Figure 5), there was no difference in the locomotor activity between ZT1 and ZT13 (Figure 4 and 5). These results are consistent with previous studies (Jones and King 2001;Gomes et al 2009;Huynh et al 2011;Ago et al 2014;Ota et al 2015;Richetto et al 2019).…”

Section: Discussionsupporting

confidence: 94%

Antidepressants with different mechanisms of action show different chronopharmacological profiles in the tail suspension test in mice

Kawai

Iwadate

Ishibashi

et al. 2019

Chronobiology International

View full text Add to dashboard Cite

The circadian system regulates sleep/wake cycles, metabolism, mood, and other functions. It also influences medication efficacy. In this study, we studied the chronopharmacological profiles of antidepressants with various modes of action. We also investigated the effects of dosing time on the pharmacological activity of several antidepressants acting on serotonergic, noradrenergic, and/or dopaminergic neurons. C57BL/6 mice were intraperitoneally administered fluoxetine, imipramine, venlafaxine, or bupropion at 08:00 h (morning), 14:00 h (mid-day), 20:00 h (evening), or 02:00 h (mid-night). Antidepressant activity was evaluated by the tail suspension test. All antidepressants reduced immobility, and their activities varied according to the dosing time. Fluoxetine and imipramine induced relatively strong rhythms with high amplitudes. Their maximal effects were observed in the morning and evening, respectively. Venlafaxine and bupropion induced weak rhythms with maximal effects in the evening and dawn, respectively. These results suggest that the antidepressant activity is associated with circadian fluctuation, and antidepressants with different modes of action have different chronopharmacological profiles. They affect locomotor activity in animals placed in novel (unfamiliar) environments. Fluoxetine, imipramine, and venlafaxine reduced locomotor activity, whereas bupropion increased it. The effects on locomotor activity also vary with circadian rhythm, and the tested drugs showed a maximal effect during the light phase. The peak time was different from that in TST. Plasma and brain levels of all drugs were slightly 3 higher in the morning than in the evening. The dosing time dependency of the antidepressant activity did not correlate with the sedative/stimulatory activity or tissue drug level. Therefore, these latter two factors may have only a small impact on circadian antidepressant activity fluctuations. The relative activity of the serotonergic, noradrenergic, and dopaminergic systems may determine the chronopharmacological profiles of each drug. These results suggest the possibility that drug therapy be optimized by considering the dosing time when the antidepressant activity is high and other pharmacological activities leading to adverse effects are low. Further studies using animal models of depression and in clinical settings are necessary to confirm the effects of dosing time on depressed subjects.

show abstract

Section: Discussionsupporting

confidence: 94%

Antidepressants with different mechanisms of action show different chronopharmacological profiles in the tail suspension test in mice

Kawai

Iwadate

Ishibashi

et al. 2019

Chronobiology International

View full text Add to dashboard Cite

show abstract

“…With the quickening pace of modern life and the increasing professional competition, the frequency of anxiety and depression is increasing, and stress might play a vital important role in the pathogeneses of anxiety and depression. Restraint has been extensively used to study the role of stress in psychopathology, especially on anxiety and depression [ 28 ]. Therefore, we applied the restraint stress model elicited by a 3-h restraint per day for a successive 10 days to induce anxiety and depression.…”

Section: Discussionmentioning

confidence: 99%

Agarwood Essential Oil Ameliorates Restrain Stress-Induced Anxiety and Depression by Inhibiting HPA Axis Hyperactivity

Wang

et al. 2018

IJMS

View full text Add to dashboard Cite

In our previous investigation, we found that agarwood essential oil (AEO) has a sedative-hypnotic effect. Sedative-hypnotic drugs usually have an anxiolytic effect, where concomitant anxiety and depression are a common comorbidity. Therefore, this study further investigated the anxiolytic and antidepressant effects of AEO using a series of animal behavior tests on a restraint stress-induced mice model. The elevated plus maze (EPM) test, the light dark exploration (LDE) test, and the open field (OF) test demonstrated that AEO has a significant anxiolytic effect. Simultaneously, the tail suspension (TS) test and the forced swimming (FS) test illuminated that AEO has an antidepressant effect with the immobility time decreased. Stress can cause cytokine and nitric oxide (NO) elevation, and further lead to hypothalamic-pituitary-adrenal (HPA) axis hyperactivity. AEO was shown to dose-dependently inhibit the levels of cytokines, including interleukin 1α (IL-1α), IL-1β, and IL-6 in serum, significantly decrease the mRNA level of neural nitric oxide synthase (nNOS) in the cerebral cortex and hippocampus, and inhibit the nNOS protein level in the hippocampus. Concomitant measurements of the HPA axis upstream regulator corticotropin releasing factor (CRF) and its receptor CRFR found that AEO significantly decreases the gene expression of CRF, and significantly inhibits the gene transcription and protein expression of CRFR in the cerebral cortex and hippocampus. Additionally, AEO dose-dependently reduces the concentrations of adrenocorticotropic hormone (ACTH) and corticosterone (CORT) downstream of the HPA axis, as measured by ELISA kits. These results together demonstrate that AEO exerts anxiolytic and antidepressant effects which are related to the inhibition of CRF and hyperactivity of the HPA axis.

show abstract

“…The elevated plus‐maze test was performed as described previously (Ago et al, ; Ota et al, ). The apparatus – consisting of two open arms (25 × 8 cm) and two enclosed arms (25 × 8 cm, surrounded by a 20‐cm‐high opaque wall) – was elevated 50 cm from the ground (BrainScience·Idea Co., Ltd., Osaka, Japan).…”

Section: Methodsmentioning

confidence: 99%

“…Locomotor activity was measured using a digital counter system with an infrared sensor (Supermex®, Muromachi Kikai Co., Ltd., Japan) as described previously (Koda et al, ; Ota et al, ). Male mice were placed individually in a novel clear polycarbonate cage (28 × 17 × 12 cm), and then locomotor activity was recorded for 20 min.…”

Section: Methodsmentioning

confidence: 99%

Anti-anhedonic effect of selective serotonin reuptake inhibitors with affinity for sigma-1 receptors in picrotoxin-treated mice

Hasebe

Ago

Watabe

et al. 2017

British Journal of Pharmacology

View full text Add to dashboard Cite

Male mice were treated with picrotoxin to decrease GABA A receptor function. Their anhedonic behaviour was measured using the female encounter test. The expression of c-Fos was determined immunohistochemically. KEY RESULTSPicrotoxin caused an anxiogenic effect on three behavioural tests, but it did not affect the immobility time in the forced swim test. Picrotoxin decreased female preference in the female encounter test and attenuated the female encounter-induced increase in c-Fos expression in the nucleus accumbens. Picrotoxin-induced anhedonia was ameliorated by fluvoxamine and S-(+)-fluoxetine, selective serotonin reuptake inhibitors with high affinity for the σ 1 receptor. The effect of fluvoxamine was blocked by a 5-HT 1A or a σ 1 receptor antagonist, and co-administration of the σ 1 receptor agonist (+)-SKF-10047 and the 5-HT 1A receptor agonist osemozotan mimicked the effect of fluvoxamine. By contrast, desipramine, duloxetine and paroxetine, which have little affinity for the σ 1 receptor, did not affect picrotoxin-induced anhedonia. The effect of fluvoxamine was blocked by a dopamine D 2/3 receptor antagonist. Methylphenidate, an activator of the prefrontal dopamine system, ameliorated picrotoxin-induced anhedonia. CONCLUSION AND IMPLICATIONSPicrotoxin-treated mice show anhedonic behaviour that is ameliorated by simultaneous activation of 5-HT 1A and σ 1 receptors. These findings suggest that the increased prefrontal dopamine release is associated with the anti-anhedonic effect observed in picrotoxin-treated mice.Abbreviations SSRI, selective serotonin reuptake inhibitor

show abstract

Anxiolytic-like effects of restraint during the dark cycle in adolescent mice

Cited by 10 publications

References 40 publications

Antidepressants with different mechanisms of action show different chronopharmacological profiles in the tail suspension test in mice

Antidepressants with different mechanisms of action show different chronopharmacological profiles in the tail suspension test in mice

Agarwood Essential Oil Ameliorates Restrain Stress-Induced Anxiety and Depression by Inhibiting HPA Axis Hyperactivity

Anti-anhedonic effect of selective serotonin reuptake inhibitors with affinity for sigma-1 receptors in picrotoxin-treated mice

Contact Info

Product

Resources

About